Granuloma annulare following initiation of interleukin‐17a antagonist
- 28 January 2021
- journal article
- letter
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 46 (5) , 924-926
Abstract
The introduction of biologics has rapidly expanded treatment options for patients suffering from severe plaque psoriasis. Currently, the mainstay of biologic therapy for psoriasis centers around three key classes: Anti‐tumor necrosis factor (TNF), Anti‐Interleukin (IL)‐23, and Anti‐IL‐17, such as Secukinumab and Ixekizumab. Though generally considered to have favorable safety profiles, there have been growing reports of dermatologic adverse events in the setting of biologic therapy initiation.Keywords
This publication has 2 references indexed in Scilit:
- Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulareJournal of the American Academy of Dermatology, 2019
- NOD2 and inflammation: current insightsJournal of Inflammation Research, 2018